a synthetic analogue of the pentasaccharide sequence in heparins
Networked: 42 relevant articles (7 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Lane, Deirdre A: 3 articles (12/2013 - 07/2011)
2. Lip, Gregory Y H: 3 articles (12/2013 - 07/2011)
3. Büller, H R: 3 articles (01/2013 - 10/2003)
4. Büller, Harry R: 3 articles (07/2011 - 03/2004)
5. Piovella, Franco: 3 articles (07/2010 - 09/2007)
6. Raskob, Gary E: 3 articles (07/2010 - 09/2007)
7. Gent, Michael: 3 articles (07/2010 - 09/2007)
8. Prins, Martin H: 3 articles (07/2010 - 09/2007)
9. Harenberg, Job: 3 articles (01/2010 - 06/2008)
10. Buller, Harry: 2 articles (12/2013 - 08/2012)

Related Diseases

1. Venous Thrombosis (Deep-Vein Thrombosis)
2. Hemorrhage
3. Venous Thromboembolism
4. Stroke (Strokes)
04/01/2008 - "Idraparinux for stroke prevention in atrial fibrillation."
04/01/2004 - "This article will (a) provide an overview of the clinical trials that form the basis for current antithrombotic guidelines in patients with AF, (b) highlight the limitations of current antithrombotic drugs used for stroke prevention, (c) briefly review the pharmacology of new antithrombotic drugs under evaluation in AF, (d) describe ongoing trials with new antiplatelet therapies and idraparinux, and completed studies with ximelagatran in patients with AF, and (e) provide clinical perspective into the potential role of new antithrombotic drugs in AF."
08/01/2006 - "Of these compounds, fondaparinux is approved for the prevention and treatment of venous thromboembolism, and idraparinux is in Phase III for venous thromboembolism treatment and stroke prevention in patients with atrial fibrillation. "
09/01/2008 - "Since inhibitors of coagulation factors Xa, VII , or II a have either not been clinically tested for their efficacy for prevention of stroke from AF, did not show a comparable effect to well-established drugs, or had excess side effects (idraparinux, ximelagatran), and since mechanical devices are highly questionable concerning their long-term effect, there is currently no alternative to oral anticoagulation with vitamin K antagonists as primary or secondary stroke prevention in high-risk AF patients."
07/01/2011 - "In large clinical trials, the oral direct thrombin inhibitor ximelagatran and the long-acting factor Xa inhibitor idraparinux were effective for reducing the risk of thromboembolic stroke, but were not marketed because of liver toxicity and excessive bleeding, respectively. "
5. Pulmonary Embolism

Related Drugs and Biologics

1. ximelagatran (Exanta)
2. Vitamin K
3. Warfarin (Coumadin)
4. Factor Xa (Coagulation Factor Xa)
5. Thrombin
6. Enoxaparin (Lovenox)
7. Blood Coagulation Factors (Coagulation Factor)
8. Acenocoumarol
9. idrabiotaparinux
10. SANORG 34006

Related Therapies and Procedures

1. Subcutaneous Injections